About RevMab Biosciences
Founded in 2012, RevMAb Biosciences develops recombinant monoclonal antibodies for research, diagnostic and therapeutic applications. The company specialises in antibody generation using a proprietary platform that avoids cell fusion and hybridoma production. This approach enables direct isolation and screening of antigen specific B cells, supporting the development of highly defined recombinant antibodies. RevMAb has particular expertise in rabbit monoclonal antibody development and validation. Its technologies support biomarker discovery, disease research and diagnostic assay development across oncology, immunology, neuroscience and other biomedical fields.
RevMAb’s portfolio includes recombinant rabbit and goat monoclonal antibodies, secondary antibodies, epitope tag antibodies and mutation specific antibodies. The catalogue contains reagents for immunohistochemistry, western blotting, flow cytometry, ELISA and cell based assays. The company is also recognised for antibodies against histone proteins, post translational modifications and clinically relevant protein variants. Antibodies are screened for specificity and affinity, then recombinantly expressed to support batch to batch consistency. These reagents help researchers investigate signalling pathways, protein expression, cancer biomarkers and disease associated mutations.
Europa Biosite’s subsidiaries distribute for RevMAb Biosciences in Belgium, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden and the United Kingdom.